LFCR
NASDAQLifecore Biomedical Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks33+150%
2026-04-262026-10-18
Mix1290d
- Other5(42%)
- SEC Filings5(42%)
- Earnings1(8%)
- Dividends1(8%)
Latest news
25 items- PRLifecore Biomedical to Participate at Upcoming Industry ConferencesCHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that the company will participate at three upcoming industry events. At each conference, Lifecore leaders will host meetings with prospective customers to discuss process development and manufacturing services for injectable programs. Details regarding Lifecore’s participation are as follows: CDMO Live Americas:Booth number: C19 Conference Dates: October 19-21, 2026Location: Boston, MAPartnership Opportunities in Drug Development (PODD)Booth number: 109 Conference Dates: Octob
- SECLifecore Biomedical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
- SECSEC Form DEFA14A filed by Lifecore Biomedical Inc.DEFA14A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
- SECLifecore Biomedical Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
- PRLifecore Biomedical to be Acquired by Webster Equity PartnersLifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% PremiumLifecore Series A Preferred Stockholders Will Receive Required "Conversion Amount" per Share in Cash at ClosingBoth Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance MilestonesStockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash and CVR at Full Performance Milestone PaymentsTransaction Expected to Support Lifecore’s Growth Objectives CHASKA, Minn. and WALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (
- PRLifecore Biomedical to Participate at CPHI Global ConferenceCHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that the company will participate at the CPHI Global Conference. The conference will take place October 6-8, 2026, in Milan, Italy. Details regarding Lifecore’s participation are as follows: CPHI Global Conference Details: Lifecore leaders, including Mark DaFonseca, chief commercial officer, and business development directors Mary Evelyn Hudson, Edward Purell, and Dan Dennehy, will host meetings with prospective customers to discuss process development and manufacturing service
- PRLifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company-- Significant New Program Positioned to Become One of Lifecore’s Largest Contracts -- -- Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Drug Product -- -- Program Expected to Contribute to 2028 Commercial Revenues -- CHASKA, Minn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced it has signed a new agreement to transfer a commercially marketed product to the company’s pipeline. Under the terms of the agreement, Lifecore will perform technical transfer services to support commercial producti
- SECSEC Form 10-Q filed by Lifecore Biomedical Inc.10-Q - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
- SECLifecore Biomedical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
- PRLifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization -- Conference Call Today at 8:00am ET CHASKA, Minn., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced results for the second quarter and six months ended June 30, 2026. CEO Commentary "The second quarter was highly productive. The effectiveness of our new business development strategy has helped us grow the value of our pipeline with consistent wins that
- PRLifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026CHASKA, Minn., July 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens. At 8:00 a.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast to discuss the results. To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations. Following the live webcast, an arc
- PRLifecore Biomedical Signs Three New Customer Agreements--Technology Transfer Agreement for Regenerative Medicine Late-Stage Development Program-- --Two Additional Agreements Supporting Early-Stage Programs Including Formulation and Development for a Global Medical Technology Company -- -- All Programs are Additive to Lifecore’s High-Value Pipeline and Expected to Contribute to 2028 Revenue -- CHASKA, Minn., July 28, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced it has signed three new customer agreements, further expanding its pipeline of early- and late-stage programs. The three agreements span multi
- PRLifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CHASKA, Minn., July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore") a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that effective on July 13, 2026, Lifecore granted a restricted stock unit ("RSU") award with respect to 3,500 shares of its common stock under Lifecore’s Equity Inducement Plan, as amended (the "Inducement Plan") to a newly hired employee of Lifecore. The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by Lifecore’s compensation committee and was granted a
- SECLifecore Biomedical Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
- PRLifecore Biomedical Signs New Agreement with Global Pharmaceutical Company--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product-- --Seventh Addition to Lifecore's Late-Stage Pipeline in Seven Months-- CHASKA, Minn., June 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced it has signed a new agreement with a global pharmaceutical company. Under the terms of the agreement, Lifecore will perform technical transfer services to support the commercial production of an injectable suspension product for neurological disorders. "With this significant new customer win, we have s
- INSIDERDirector Kiper Christopher S was granted 25,907 shares (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Obus Nelson was granted 25,907 shares, increasing direct ownership by 19% to 164,100 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Aryeh Jason was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Korenberg Matthew E was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Schechter Joshua was granted 25,907 shares, increasing direct ownership by 24% to 133,080 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Antunes Humberto Calheiros was granted 25,907 shares, increasing direct ownership by 55% to 72,967 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Johnson Paul Harold was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Houde Lovas Katrina was granted 25,907 shares, increasing direct ownership by 24% to 135,319 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- SECLifecore Biomedical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
- PRLifecore Biomedical Signs Agreement with New Biopharmaceutical Customer-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn., June 02, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it has signed a manufacturing services agreement with a leading provider of ophthalmic disease management solutions. Under the terms of the agreement, Lifecore will perform process development and technical transfer services in support of anticipated commercial manufacturing upon regulatory
LFCR FAQ
5 questionsWhere does LFCR stock trade?
Lifecore Biomedical Inc. (LFCR) is listed on NASDAQ.What sector and industry is LFCR in?
Lifecore Biomedical Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about LFCR?
Lifecore Biomedical Inc. has had 6 recent analyst actions on file. The most recent action was from Barrington Research: Outperform with a $550.00 price target on 2026-03-17. Recent price targets range from $200.00 to $800.00.What companies are similar to LFCR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LFCR side-by-side with any of them on Quantisnow.How can I track LFCR on Quantisnow?
Quantisnow aggregates Lifecore Biomedical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LFCR to receive live email and push alerts on every new disclosure.